Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07718399
Starting soon Not applicable

Spirulina Supplementation in Postmenopausal Women

NCT07718399 · tracked via the Priya Life Science Turkey tracker
Sponsor
Halic University
Phase
Not applicable
Started
2026-07
Last updated
2026-07-22

Condition(s) studied

PostmenopauseOverweight

Investigational drug(s) / intervention(s)

SpirulinaPlacebo

Spirulina: Participants will receive 2 g/day spirulina tablets for 8 weeks.

Placebo: Participants will receive matching placebo tablets for 8 weeks.

Study summary

The purpose of this study is to investigate the effects of spirulina supplementation on weight gain associated with menopause, changes in metabolic parameters, sleep quality, and markers of depression in mildly overweight postmenopausal women, and to evaluate the changes that occur in these parameters.

Eligibility

Sex
FEMALE
Min age
45 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Volunteering to participate in the study * Having a body mass index (BMI) between 25 and 29.9 kg/m² * Having no chronic illnesses * Being between the ages of 45 and 65 * Being postmenopausal * Willing to consume the provided supplement * Individuals who can read and write in Turkish and are open to communication. Exclusion Criteria: * Having a chronic condition such as diabetes, hypertension, cancer, metabolic syndrome, chronic kidney disease, dyslipidemia, etc. * Having a congenital metabolic disorder * Being in the experimental group but not taking the supplement regularly * Taking medication to lower blood lipids * Having an allergy to any food * Not being in the postmenopausal period

Primary outcome measure(s)

  • Fasting Blood Glucose — Baseline and Week 8
    Fasting blood glucose (mg/dL) will be measured at baseline and Week 8 to evaluate the effect of spirulina supplementation.
  • HbA1c — Baseline and Week 8
    HbA1c (%) will be measured at baseline and Week 8 to assess long-term glycemic control.
  • HOMA-IR — Baseline and Week 8
    Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) will be calculated using fasting glucose and fasting insulin measurements obtained at baseline and Week 8.
  • Total Cholesterol — Baseline and Week 8
    Total cholesterol concentration (mg/dL) will be measured at baseline and Week 8.
  • LDL Cholesterol — Baseline and Week 8
    Low-density lipoprotein (LDL) cholesterol concentration (mg/dL) will be measured at baseline and Week 8.
  • HDL Cholesterol — Baseline and Week 8
    High-density lipoprotein (HDL) cholesterol concentration (mg/dL) will be measured at baseline and Week 8.
  • Triglycerides — Baseline and Week 8
    Serum triglyceride concentration (mg/dL) will be measured at baseline and Week 8.

Trial sites (1)

FacilityCityRegionStatus
Haliç University Faculty of Health Sciences Istanbul eyüpsultan

More Halic University trials in Turkey

Respiratory Muscle Strength and Jiu-Jitsu-Specific Performance in Male Brazilian Jiu-Jitsu Athletes Starting soon
Effects of Balance Exercises Performed With Different Visual Stimuli Starting soon
First Aid Needs of Female Agricultural Workers and the Impact of Basic First Aid Training on Their Knowledge Levels Active, not recruiting
Osteopathy in Postpartum Lumbopelvic Pain Active, not recruiting
Factors Associated With Disability in Postpartum Lumbopelvic Pain Starting soon

Other trials for the same condition

ACT-Based Group Therapy and Mobile Application Intervention for Emotional Eating Starting soon
Motivational Interviewing for Overweight and Obese Adults at Healthy Life Centers Starting soon
The Effect of Sujok Therapy on Urinary Incontinence and Quality of Life in Postmenopausal Women Active, not recruiting
Dance-Based Exercise Versus Clinical Pilates in Women With Overweight or Obesity Starting soon
On the Effect of a Hybrid Health Literacy Intervention on Sexual Function and Digital Health Literacy in Menopausal Women Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07718399 on ClinicalTrials.gov ↗ ← All trials in Turkey